TMCnet News
Engage with Pluri's Talent: Exciting Conference Appearances AheadHAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences. Conference: Bio-Europe Spring Conference: Advanced Therapies 2024 Conference: CISH Impact Investments Holdings Conference Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at [email protected] About Pluri Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services. To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X. Media Contacts Investors: [email protected] Israel Media: Shachar Yental at [email protected] U.S. Media: Madeline Weirman at [email protected]/ Jessica Daitch at [email protected] |